Purpose: To retrospectively investigate the impact of prostate specific antigen (PSA) level after neoadjuvant androgen- deprivation therapy (ADT) on biochemical relapse-free survival in patients with prostate cancer who received radical radiotherapy (RT).
Methods: Between March 2003 and March 2008, 128 men with localized prostate cancer underwent neoadjuvant ADT for 4-6 months followed by radical RT. Biochemical relapse-free survival was compared between patients with pre-RT PSA ≤ 0.1 vs > 0.1 ng/mL.
Results: At a median follow up of 47.3 months, biochemical relapse-free survival was significantly higher in patients with a pre-RT PSA ≤ 0.1 ng/mL compared with pre-RT PSA > 0.1 ng/mL (85.6 vs 63.2%, p = 0.0025).
Conclusion: The current analysis demonstrating better treatment outcome in patients with excellent biochemical response to neoadjuvant ADT, supports an individualized treatment strategy.
Written by:
Dolezel M, Odrazka K, Vanasek J, Vaculikova M, Vlkova-Sefrova J, Jansa J, Macingova Z, Brodak M, Hartmann I, Melichar B. Are you the author?
Oncology Centre, Multiscan α Pardubice Regional Hospital, Pardubice, Czech Republic.
Reference: J BUON. 2013 Oct-Dec;18(4):949-53.
PubMed Abstract
PMID: 24344022
UroToday.com Prostate Cancer Section
